Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2004

View Archived Issues

Studies highlight pimecrolimus efficacy in children with atopic dermatitis

New Glimicron presentation launched in Japan

McNeil and ICAgen enter agreement for ICA-17043 for sickle cell anemia

Grant for Alzheimer's diagnostic work at Samaritan and Georgetown University

Cytorex Biosciences completes cytotoxicity testing with Cytoreg

OPT-CHF phase II study of oxypurinol recommended to continue

NeuTec reports positive data for Mycograb

Adherex Technologies updates status of two key programs

GlaxoSmithKline and Biota hepatitis C collaboration to conclude

Copackage of Combivir and Viramune planned for developing world

Ortho-Clinical Diagnostics acquires rights to NT-proBNP by Roche Diagnostics

ZyComb shows efficacy and safety in phase III study

UCB offer for Celltech is successful

Fast track status for pixantrone in aggressive NHL

Pain Therapeutics' efforts in neuropathic pain supported by NIH grant

Pharmacokinetics of capravirine regimens assessed in healthy subjects

Studies reveal efficacy of tenofovir in HBV/HIV co-infected patients

Promising safety and pharmacokinetic profile of AMD-070 in healthy subjects

Long-term efficacy and safety of enfuvirtide in HIV-infected patients

Reverset shows antiviral efficacy in HIV-infected patients

Antibacterial oxazolidinones in development at Pfizer

Vertex claims protein kinase inhibitors

Aldosterone synthase inhibitors reported by Novartis

Fluorinated amides disclosed by Pfizer

Oxford GlycoSciences claims antiangiogenic agents

Multilayered tablet claimed by Bristol-Myers Squibb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...